Your browser doesn't support javascript.
loading
Exposure-Response-Based Product Profile-Driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer.
Zhu, Rui; Poland, Bill; Wada, Russ; Liu, Qi; Musib, Luna; Maslyar, Daniel; Cho, Eunpi; Yu, Wei; Ma, Han; Jin, Jin Yan; Budha, Nageshwar.
Affiliation
  • Zhu R; Genentech, Inc., South San Francisco, California, USA.
  • Poland B; Certara, Menlo Park, California, USA.
  • Wada R; Certara, Menlo Park, California, USA.
  • Liu Q; Genentech, Inc., South San Francisco, California, USA.
  • Musib L; Genentech, Inc., South San Francisco, California, USA.
  • Maslyar D; Genentech, Inc., South San Francisco, California, USA.
  • Cho E; Genentech, Inc., South San Francisco, California, USA.
  • Yu W; Genentech, Inc., South San Francisco, California, USA.
  • Ma H; Genentech, Inc., South San Francisco, California, USA.
  • Jin JY; Genentech, Inc., South San Francisco, California, USA.
  • Budha N; Genentech, Inc., South San Francisco, California, USA.
CPT Pharmacometrics Syst Pharmacol ; 8(4): 240-248, 2019 04.
Article in En | MEDLINE | ID: mdl-30762302
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Pyrimidines / Prostatic Neoplasms, Castration-Resistant / Antineoplastic Agents Type of study: Risk_factors_studies Limits: Humans / Male Language: En Journal: CPT Pharmacometrics Syst Pharmacol Year: 2019 Document type: Article Affiliation country: United States Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Pyrimidines / Prostatic Neoplasms, Castration-Resistant / Antineoplastic Agents Type of study: Risk_factors_studies Limits: Humans / Male Language: En Journal: CPT Pharmacometrics Syst Pharmacol Year: 2019 Document type: Article Affiliation country: United States Country of publication: United States